$BMY · BRISTOL MYERS SQUIBB CO SEC Filings
Position Tracker tracks 12 SEC EDGAR filings for BRISTOL MYERS SQUIBB CO ($BMY) from August 26, 2026 through October 29, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 1 Form 8-K current event disclosures, and 9 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$BMY 10-Q — BRISTOL MYERS SQUIBB CO
BMS's top-line growth story remains intact but margin pressure from aggressive external pipeline spending and the end of a lucrative royalty stream creates a more complex earnin…
$BMY 8-K — BRISTOL MYERS SQUIBB CO
BMY delivered a rare combination: a revenue beat and guidance raise paired with a material EPS guidance cut, forcing investors to weigh top-line momentum against deteriorating p…
$BMY 4 — Bristol-Myers Squibb Company
This Form 4 filing reports changes in beneficial ownership for Cari Gallman, Executive Vice President and General Counsel of Bristol-Myers Squibb Company. The reported transacti…
$BMY 4 — Bristol-Myers Squibb Company
This Form 4 filing reports a change in beneficial ownership by Phyllis R. Yale, a director of Bristol-Myers Squibb Company. On September 30, 2026, Ms. Yale acquired 560.897 defe…
$BMY 4 — Bristol-Myers Squibb Company
Bristol-Myers Squibb Company filed a Form 4 reporting a change in beneficial ownership for director Theodore R. Samuels II. The filing states that on September 30, 2026, Samuels…
$BMY 4 — Bristol-Myers Squibb Company
This SEC Form 4 filing reports a change in beneficial ownership by Derica W. Rice, a director of Bristol-Myers Squibb Company. On September 30, 2026, Rice acquired 620.994 defer…
$BMY 4 — Bristol-Myers Squibb Company
Bristol-Myers Squibb filed a Form 4 with the SEC on October 2, 2026, reporting a change in beneficial ownership for Michael R. McMullen, a director of the company. The filing st…
$BMY 4 — Bristol-Myers Squibb Company
Bristol-Myers Squibb Company filed a Form 4 reporting a change in beneficial ownership for Peter J. Arduini, a director of the company. According to the filing, on September 30,…
$BMY 4 — Bristol-Myers Squibb Company
This SEC Form 4 reports a change in beneficial ownership for Cristian Massacesi, an officer of Bristol-Myers Squibb Company listed as EVP, Chief Medical Officer, and Head of Dev…
$BMY 144 — Bristol-Myers Squibb Company
Bristol-Myers Squibb Company filed a Form 144 notice with the SEC on September 9, 2026. The filing reports a proposed sale of company common stock by Cristian Massacesi, identif…
$BMY 4 — Bristol-Myers Squibb Company
The SEC Form 4 filed by Bristol-Myers Squibb Company on September 3, 2026 reports transactions by Wendy Short Bartie, the company’s Executive Vice President, Corporate Affairs.…
$BMY 4 — Bristol-Myers Squibb Company
Bristol-Myers Squibb Company filed a Form 4 with the SEC on August 26, 2026, reporting a change in beneficial ownership for Phil M. Holzer, the company’s Senior Vice President a…